TOTAL AND HIGH-MOLECULAR WEIGHT ADIPONECTIN LEVEL IN HYPERTENSIVE WOMEN WITH ABDOMINAL OBESITY

Objective. To assess total and high-molecular weight adiponectin (AN) and (HMWAN) level in women with abdominal obesity (AO) and arterial hypertension (HTN) — citizens of St Petersburg aged 30–55 years old.

 Design and mеthods. We examined 94 women with AO (IDF, 2005), mean age 45,3 ± 0,1 years. Compari-son group included 16 healthy women without АО. The levels of AN, HMWAN and insulin were determined by ELISA method (DRG, USA). Serum lipids were determined by enzymatic method (COBAS INTEGRA 400/700/800, Germany). The homeostasis model was used to assess the insulin resistance HOMA-IR.

 Results. HTN was diagnosed in 48,4 % women with АО (IDF, 2005). The level of total and high-molecular weight adiponectin was lower in subjects with АО compared to the healthy women (р < 0,05). Total AN level did not differ in hypertensive women with АО and in the normotensive subjects (р > 0,05). However, the HMWAN level was lower in hypertensive subjects with АО compared to the normotensive women (р < 0,01). The highest insulin level and НОМА-IR were found in hypertensive women with АО and the lowest level of total AN (1st tertil). At the same time women with the lowest HMWAN concentration (1st tertil) had the highest levels of systolic and diastolic blood pressure (BP), waist circumference, insulin, glucose, triglycerides and НОМА-IR. Linear regression analysis confirmed the correlation between the levels of HMWAN and BP (β = –0,21, р = 0,03).

Conclusions. The high-molecular weight adiponectin level is lower in women with AO and HTN compared to the normotensive subjects with AO. Low level of high-molecular weight adiponectin might be considered a factor for HTN development in women with AO.

1. Pi-Sunyer F.X. The epidemiology of central fat distribution in relation to disease // Nutrition Reviews. — 2004. — Vol. 62, № 7. — Р. 120–126.

2. Galic S., Oakhill J.S., Steinberg G.R. Adipose tissue as an endocrine organ // Mol. Cell. Endocrinol. — 2010. — Vol. 316, № 2. — Р. 129–139.

3. Yamauchi T., Kamon J., Waki H. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity // Nat. Med. — 2001. — Vol. 7, № 8. — Р. 941–946.

4. Ohashi K., Ouchi N., Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectin // Biochimie. — 2012. —Vol. 94, № 10. — Р. 2137–2142.

5. Han S., Quon M., Kim J. et al. Adiponectin and cardiovascular disease // J. Am. Coll. Cardiol. — 2007. — Vol. 49, № 5. — P. 531–538.

6. Беляева О.Д., Баженова Е.А., Березина А.В. и др. Уровень адипонектина, показатели липидного и углеводного обменов у пациентов с абдоминальным ожирением // Артериальная гипертензия. — 2009. — Т. 15, № 3. — С. 309–314. / Belyaeva O.D., Bazhenova E.A., Berezina A.V. et al. Adiponectin levels, lipid profile and glucose metabolism in patients with abdominal obesity // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2009. — Vol. 15, № 3. — P. 309–314 [Russian].

7. Matsubara M., Maruoka S., Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia // J. Clin. Endocrinol. Metab. — 2002. — Vol. 87, № 6. — P. 2764–2769.

8. Huang K., Chen C., Chuang L. et al. Plasma adiponectin levels and blood pressures in non-diabetic adolescent females // J. Clin. Endocrinol. Metab. — 2003. — Vol. 88, № 9. — P. 4130–4134.

9. Танянский Д.А., Парфенова Н.С. Адипонектин: благоприятное воздействие на метаболические и сердечно-сосудистые нарушения // Артериальная гипертензия. — 2013. — T. 19,

10. № 1. — С. 84–96. / Tanyanskiy D.A., Parfenova N.S. Adiponectin: the beneficial effects on metabolic processes and cardiovascular system // Arterial Hypertension [Arterialnaya Gipertenziya]. —2013. — Vol. 19, № 1. — P. 309–314 [Russian].

11. Hara K., Horikoshi M., Yamauchi T. et al. Measurement of the high-molecular-weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome // Diabetes Care. — 2006. — Vol. 29, № 6. — Р. 1357–1362.

12. Heidemann C., Sun Q., van Dam R.M. et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women // Ann. Intern. Med. — 2008. — Vol. 149, № 5. — Р. 307–316.

13. Sattar N., Watt P., Cherry L. et al. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study // J. Clin. Endocrinol. Metab. — 2008. — Vol. 93, № 5. — Р. 1846–1849.

14. Pischon T., Hu F.B., Girman C.J. et al. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women // Atherosclerosis. — 2011. — Vol. 219, № 1. — Р. 322–329.

15. Aso Y., Yamamoto R., Wakabayashi S. et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin // Diabetes. — 2006. — Vol. 55, № 7. — Р. 1954–1960.

16. Kim D.H., Kim C., Ding E.L. et al. Adiponectin Levels and the risk of hypertension: a systematic review and meta-analysis // Hypertension. — 2013. — Vol. 62, № 1. — Р. 27–32.

17. Kawamoto R., Tabara Y., Kohara K. et al. Association of serum high molecular weight adiponectin and blood pressure among non-diabetic community-dwelling men // Clin. Experim. Hypertens. — 2011. — Vol. 33, № 5. — Р. 336–44.

18. Ogorodnikova A.D., Wassertheil-Smoller S., Mancuso P. et al. High-molecular-weight adiponectin and incident ischemic stroke in postmenopausal women: a Women's Health Initiative Study // Stroke. — 2010. — Vol. 41, № 7. — Р. 1376–1381.

19. Baumann M., von Eynatten M., Dan L. et al. Altered molecular weight forms of adiponectin in hypertension // J. Clin. Hypertens. — 2009. — Vol. 11, № 1. — Р. 11–16.

20. Alberti G. Introduction to the metabolic syndrome // Eur. Heart J. Suppl. — 2005. — Vol. 7, Suppl. D. — P. D3–D5.

21. Garrow J.S., Webster J. Quetelet's index (W/H2) as a measure of fatness // Int. J. Obes. — 1985. — Vol. 9, № 2. —Р. 147–153.

22. Matthews D., Hosker J., Rudenski D. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. — 1985. — Vol. 28, № 7. — P. 412–419.

23. The European cardiovascular disease risk assessment model. — [Electronic resource]. — URL: http://www.escardio.org (дата обращения — 10.10.2013).

24. Manson J.E., Skerrett P.J., Greenland P. et al. The escalating pandemic of obesity and sedentary lifestyle. A call to action for clinicians // Arch. Intern. Med. — 2004. — Vol. 164, № 3. — Р. 249–258.

25. Poirier P., Giles T.D., Bray G.A. et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss : an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the obesity committee of the Council on nutrition, physical activity, and metabolism // Circulation. — 2006. — Vol. 113, № 6. — Р. 898–919.

26. Yusuf S., Hawken S., Ounpuu S. et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER-HEART study): case-control study // Lancet. — 2004. — Vol. 364, № 9438. — Р. 937–952.

27. Stamler J., Rose G., Stamler R. et al. INTERSALT study findings. Public health and medical care implications // Hypertension. — 1989. — Vol. 14, № 5. — Р. 570–577.

28. Garrison R.J., Kannel W.B., Stokes J.I. et al. Incidence and precursors of hypertension in young adults; the Framingham Offspring Study // Prevent. Med. — 1987. — Vol. 16, № 2. —Р. 235–251.

29. Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease // Obes. Res. — 2003. — Vol. 11, № 11. — Р. 1278–1289.

30. Sinha R., Dufour S., Petersen K.F. et al. Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relation-ships to insulin sensitivity, total body fat, and central adiposity // Diabetes. — 2002. — Vol. 51, № 4. — Р. 1022–1027.

31. Yusuf S., Hawken S., Ounpuu S. et al. INTERHEART Study Investigators: Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study // Lancet. — 2005. — Vol. 366, № 9497. — Р. 1640–1649.

32. Katzmarzyk P.T., Craig C.L. Independent effects of waist circumference and physical activity on all-cause mortality in Canadian women // Appl. Physiol. Nutr. Metab. — 2006. — Vol. 31, № 3. — Р. 271–276.

33. Rocchini A.P. Obesity hypertension, salt sensitivity and insulin resistance // Nutr. Metab. Cardiovasc. Dis. — 2000. — Vol. 10, № 5. — Р. 287–294.

34. Hall J.E. The kidney, hypertension and obesity // Hypertension. — 2003. — Vol. 41, № 3. — Р. 625–633.

35. Асташкин Е.И., Глезер М.Г. Ожирение и артериальная гипертония // Проблемы женского здоровья. — 2008. — Т. 3, № 4. — С. 23–33. / Astashkin Ye.I., Glezer M.G. Obesity and arterial hypertension // Problems of Women Health [Problemy Zhenskogo Zdorovia]. — 2008. — Vol. 3, № 4. — С. 23–33 [Russian].

36. Ahima RS., Flier JS. Adipose tissue as an endocrine organ // Trends Endorinol. Metab. — 2000. — Vol. 11, № 8. —Р. 327-332.

37. Fruhbeck G., Gomez-Ambrosi J., Muruzabal F.J. et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation // Am. J. Physiol. Endocrinol. Metab. — 2001. — Vol. 280, № 6. — Р. E827–E847.

38. Чубенко Е. А. Уровень лептина, структурно-функциональные параметры сердца и сосудов у женщин с абдоминальным ожирением и артериальной гипертензией: автореферат дис. ... канд. мед. наук: 14.00.06; Санкт-Петербург. гос. мед. ун-т им. акад. И. П. Павлова. — СПб., 2009. — 16 с. / Chubenko E.A. Leptin level, structural and functional features of heart and vessels in women with abdominal obesity and hypertension: PhD thesis: 14.00.06; St Petersburg Pavlov State Medical University. — St Petersburg, 2009. — 16 p. [Russian].

39. Weyer C., Funahashi T., Tanaka S. et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia // J. Clin. Endocrinol. Metab. — 2001. — Vol. 86, № 5. — Р. 1930–1935.

40. Di Chiara T., Argano C., Corrao S., Scaglione R., Licata G. Hypoadiponectinemia: a link between visceral obesity and metabolic syndrome // J. Nutr. Metab. — 2012. — Vol. 2012. — 175245. doi: 10.1155/2012/175245.

41. Pajvani U.B., Du X., Combs T.P. et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity // J. Biol. Chem. — 2003. — Vol. 278, № 11. — P. 9073–9085.

42. Kobayashi H., Ouchi N., Kihara S. et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin // Circ. Res. — 2004. — Vol. 94, № 4. — Р. 27–31.

43. Okamoto Y., Kihara S., Ouchi N. et al. Adiponectin reduces atherosclerosis in apolipoprotein K-deficient mice // Circulation. — 2002. — Vol. 106, № 22. — Р. 2767–2770.

44. Kubota N., Terauchi Y., Yamauchi T. et al. Disruption of adiponectin causes insulinresistance and neointimal formation // J. Biol. Chem. — 2002. — Vol. 277, № 29. — Р. 25863–25866.

45. Canale M.P., Manca di Villahermosa S., Martino G. Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity // Int. J. Endocrinol. — 2013. — Vol. 2013.

46. Landsberg L. Hyperinsulinemia: possible role in obesity induced hypertension // Hypertension. — 1992. — Vol. 19, № 1. — Р. 161–166. — 865965. doi: 10.1155/2013/865965.